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Introduction
The fecal egg count reduction test (FECRT) remains the recommended assay to assess anthelmintic drug efficacy against gastrointestinal nematodes in animals, and hence anthelmintic resistance (Kaplan and Vidyashankar, 2012) . Guidelines for performing a FECRT were provided in the 1992 World Association for the Advancement of Veterinary Parasitology (WAAVP) publication on how to detect anthelmintic resistance in nematodes of veterinary importance (Coles et al., 1992) . Since the publication of these guidelines, a variety of studies have provided novel insights into how to best design (e.g., Torgerson et al., 2005; McKenna, 2006; Dobson et al., 2012; Levecke et al. 2012; Calvete and Uriarte, 2013) , analyze (e.g., Vercruysse et al., 2001; Cabaret and Berrag, 2004; Dobson et al., 2009 Vercruysse et al., 2011; Vidyashankar et al., 2012; Calvete and Uriarte, 2013) and interpret a FECRT (e.g., Vidyashankar et al., 2007 , Torgerson et al., 2005 Denwood et al., 2010; Dobson et al., 2012; Lyndal-Murphy et al., 2014; Geurden et al., 2015) .
These new insights point to the need for an update of the recommendations for the FECRT.
However, it is not straightforward to provide guidance that allows improving both the standardization and the performance of the FECRT across a variety of both animal and parasite species. For example, it is well known that the required sample size and the lower analytic sensitivity of the fecal egg count (FEC) method (≈ 1 / mass of feces in gram examined under the microscope) will depend on the underlying level (or intensity) and aggregation of egg excretion (Levecke et al., 2012) . However, these two egg excretion parameters vary considerable between and within both parasite and animal species, and are often unknown prior the FECRT, making it difficult to recommend one study design that applies to all possible scenarios of egg excretion while assuring the reliable performance of a
FECRT. An approach that may untangle this complex issue is to make recommendations on the total number of eggs that need to be counted under the microscope at baseline, a strategy A C C E P T E D M A N U S C R I P T that has been previously applied by Dobson et al., 2012 . Traditionally, the eggs counted are converted into eggs per gram (EPG), and those data are then used for calculating percent reduction in FECs and the corresponding uncertainty intervals (UI, confidence intervals in case of frequentist methods and credible intervals in case of Bayesian methods). However, the eggs counted under the microscope are the actual data recorded in a FECRT; hence it is an important parameter with regard to both analytical issues and study design. For example, when FECR is based on the pre-and post-treatment FECs of the same animals and when all pre-and post-treatment samples are examined applying a FEC the same analytic sensitivity, the formula can be reduced to the ratio of the total number of eggs counted under the microscope at pre-and post-treatment (see Equations 1 and 2; Supplementary Material 1).
Additionally, the total number of eggs counted under the microscope nicely grasps the variations in both study design (analytic sensitivity and sample size) and host-parasite interactions (level and aggregation of egg excretion), and hence recommending a minimum number of eggs to be counted under the microscope (also dependent on the examined sample size) allows avoiding stringent recommendations on the other parameters. As an example, if it were recommended to count at least 200 eggs under the microscope across at least 10 animals prior treatment and if animals were excreting on average 500 EPG, one could either screen 10 animals using a diagnostic technique with a analytic sensitivity of 25 EPG (10 animals x 500 EPG / 25 EPG = 200 eggs) or screen 20 animals with a analytic sensitivity of 50 EPG (20 animals x 500 EPG / 50 EPG = 200 eggs). In addition, it would also allow avoiding underpowered trials when egg excretion at baseline revealed to be lower as anticipated or when the level of egg excretion is even unknown. When we now assume that the animals excrete 250 EPG instead of 500 EPG, the total number of eggs at baseline would be 100 for both study designs (= 10 animals x 250 EPG / 25 EPG = 20 animals x 250 EPG / 50 EPG), and hence the trials may not allow to readily draw conclusions on the drug efficacy. At this
point, one could easily adapt the diagnostic strategy until a sufficient number of eggs are counted at baseline (e.g. reexamination of the same samples with the same diagnostic technique would in principle double the eggs counted). Although these examples illustrate the elegance of recommending a minimum number of eggs to be counted under the microscope we currently lack the evidence to recommend the number of eggs required to yield a reliable assessment of drug efficacy by means of the FECRT. Lastly, it is also important to avoid having most eggs counted come from only few animals, and hence guidance on the allowed distribution of egg counts across animals is also needed.
Other aspects of analysis and interpretation of the FECRT that need further research are the methodology of calculating the corresponding UIs and the criteria for classifying drug efficacy into 'normal', 'suspected' and 'reduced'. The UI methodology in the current guidelines has two important limitations. First, it can only be applied on a randomized controlled study design using post-treatment counts of both treatment and control groups (Coles et al., 1992) . This experimental design, however, has proven to be less sensitive at detecting reduced efficacy compared to FECRT based on pre-and post-treatment counts from the same animals (McKenna, 2006; Dobson et al. 2012; Calvete and Uriarte, 2013) . Second, the uncertainty of the estimates (the UI) cannot be calculated when the observed FECR is 100%, and hence it is impossible to draw conclusions on the reliability of the estimate (Denwood et al., 2010; Dobson et al., 2012; Torgerson et al., 2014) . This is relevant because seeing no eggs following treatment does not mean the efficacy was 100%; depending on how many eggs were counted in the pre-treatment FECs the true efficacy may be approaching 100%, but may never reach 100% (or be considerably less than 100%). Alternative UI methodologies can be applied to FECRT based on counts of the same animals (Denwood et al., 2010; Lyndal-Murphy et al., 2014; Torgerson et al., 2014; Levecke et al., 2015; Geurden et al., 2015; Peña-Espinoza et al., 2016) . Other methods allow assessment of the uncertainty
of estimates when FECR is 100% (Denwood et al., 2010; Dobson et al., 2012; Torgerson et al., 2014; Geurden et al., 2015; Peña-Espinoza et al., 2016) . However, at present these methodologies need further research, thus the accuracy and precision of these methods requires further clarification. Currently, the efficacy of an anthelmintic is classified as 'reduced', 'suspected' and 'normal' based on how the obtained FECR and the lower limit (LL) of the 95% UI relates to established thresholds, a drug efficacy for sheep and goats being 'reduced' when FECR <95% and LL of UI <90%; as 'suspected' when either FECR <95% or LL <90%, and as 'normal' when FECR ≥95% and LL ≥90% (Coles et al., 1992) . Whether alternative classification criteria that are solely based on the UI (e.g. drug efficacy being 'reduced' when upper limit (UL) <95%, 'normal' when LL ≥95%, and 'suspected' in any other cases; El-Abdellati et al., 2010) or combining both the FECR-estimate and the UI (Lyndal-Murphy et al., 2014; Geurden et al., 2015 ; 'normal': FECR ≥95%, UL of UI ≥95% and LL of UI ≥90%; 'reduced': FECR <95%, UL of UI <95% and LL of UI <90%;
'suspected' in all other cases), or only the FECR estimate (e.g., drug efficacy being 'reduced' when FECR <90%, 'normal' when FECR ≥95%, and 'suspected' in any other cases; in analogy with World Health Organization, 2013) would allow for reliable detection of reduced drug efficacy is unclear.
The aim of this study is to provide insights complementary to the current knowledge on how to design, analyze and interpret FECRTs, and to ultimately provide guidance in the development of new standardized guidelines for the FECRT that lead to improving both the standardization and the analytical performance of the FECRT across a variety of both animal and parasite species.
Methods
The study consisted of two consecutive procedures. First, data were generated using a simulation in which the 'true' drug efficacy (TDE) was evaluated by the FECRT under varying scenarios of sample size, analytic sensitivity of the diagnostic technique and level of both intensity and aggregation of egg excretion. Second, the obtained data were analyzed with the aim (i) to verify which classification criteria allows for reliable detection of reduced drug efficacy, (ii) to identify the UI methodology that yields the most reliable assessment of precision of drug efficacy, coverage of TDE and detection of reduced drug efficacy, and (iii) to determine the required sample size and number of eggs counted under the microscope that optimizes the detection of reduced efficacy.
Data generation
Data were generated by Monte Carlo simulation using a modification of the methodology described by Levecke et al. (2012) . First, the distribution of parasites within a virtual host population before treatment was defined by a negative binomial distribution. This distribution is determined by two parameters: the mean level of intensity (mean pre-treatment fecal egg counts (pre-FECs)) and aggregation of egg excretion across animals (k). Low values of k indicate that only few animals are excreting the majority of the eggs, high values indicate that egg counts are more equally distributed across the host population. From this pre-defined distribution representing a virtual population of animals, a random sample of 5,000 FECs was randomly drawn. This number of FECs was required to ensure a sufficiently large number of unique non-zero FEC cases. Using this method, the 'observed' pre-FEC will be different from the 'true' pre-FEC due to the variation (i.e. stochasticity) introduced by sampling eggs associated with the diagnostic technique. This component of variation was simulated using the Poisson distribution defined by the expected number of eggs counted (i.e. 'true' pre-FEC/analytic sensitivity). Subsequently, a subset of N animals was randomly drawn from all
animals found to be excreting eggs (observed pre-FEC >0) at baseline. The 'true' FECs after treatment (post-FECs) were generated from the binomial distribution with the 'true' pre-FECs as the number of trials and 1-TDE as the proportion. The observed FECs after treatment (postFECs) were generated as described above for the pre-FECs. Subsequently, the FECR and its corresponding 95% UI were determined. The FECR was calculated as described in the formula below (Kochapakdee, 1995 The LL and UL of the 95% UI of FECR equal 1 -97.5 th quantile and 1 -2.5 th quantile of the Gamma distribution with a shape parameter γ and a scale parameter θ, respectively. Based on the FECR, its variance and a sample size N, one can write the two parameters of the Gamma
The second methodology (method 2) is based on the 95% UI described in Coles et al., 1992, but accounting for correlation between individual FECs before and after treatment and assuming that the naturally log transformed ratio of mean post-FEC and mean pre-FEC follows a t-distribution with N-1 degrees of freedom (Lyndal-Murphy et al., 2014) . Applying this methodology, the variance of the log transformed ratio equals to 25 with a step-wise interval of 5. The TDE ranged from 70 to 99% with a step-wise interval of 1%, resulting in 36,000 combinations (8 (mean pre-FEC) x 6 (k) x 5 (analytic sensitivity) x 5 (sample size) x 30 (TDE)) that were each iterated 100 times.
Statistical data analysis
2.2.1. Comparison of the diagnostic performance of four classification criteria for drug efficacy Four criteria, each classifying the drug efficacy as 'reduced', 'suspected' and 'normal', were included in the comparison. The first criteria (criteria 1) refer to the current definition (Coles et al., 1992) , classifying drug efficacy as 'reduced' when FECR <95% and LL of the 95% UI WHO, 2013) . To compare the performance of the different classification criteria, they were each applied on the dataset generated. Subsequently, the ability of each criteria to correctly classify a truly reduced and normal drug efficacy were determined. To this end, every TDE <95% was considered as a truly reduced efficacy, and as truly normal if ≥95%.
The calculation of the UI was based on method 1.
Comparison of coverage and diagnostic performance of two 95% UI methodologies
The two methodologies for calculating 95% UIs were compared based on the coverage (proportion of the 95% UIs that contains the TDE; which should be 95%), and their ability to correctly classify a truly reduced and normal drug efficacy based on classifications criteria 1, 2 and 3. Classification criteria 4 were not included in this comparison since it classifies drug efficacy based on the FECR estimates only.
The required samples size and number of eggs counted under the microscope
The required sample size and number of eggs that need to be counted in order to correctly define a truly reduced and normal efficacy were determined. To this end, fully parameterized logistic regression models were fitted separately for the detection of truly reduced (sensitivity) and truly normal drug efficacies (specificity) with the test result based on the most reliable classification criteria for drug efficacy (positive/negative) as the outcome, and the TDE, the sample size, the number of eggs counted and all possible interaction between the variables as covariates. Models were built for both 95% UI methodologies. The predictive power of these models was evaluated by the proportion of the observed outcome that was correctly predicted by the model. To this end, an individual probability >0.5 was set as a positive test result, and negative if different. Finally, the required number of eggs to be counted for correct classification of drugs as 'reduced' and 'normal' in at least 95% of the cases was estimated based on this model for each sample size across a selected range of TDE-values (87%-89%; 97%-99%). To this end, the probability of classifying a truly reduced or normal drug efficacy was estimated for a wide range of scenarios of sample size and number of eggs counted.
Results

Comparison of the diagnostic performance of four classification criteria for drug efficacy
The sensitivity and the specificity of detecting a truly reduced efficacy for each of the four classification criteria are summarized in Table 1 . As illustrated in Figure 1 the sensitivity and specificity varied across different values of TDE, with the probability of correctly classifying drug efficacy decreasing as the TDE approached the threshold of 95% (surface of grey zone increases). For example, when applying criteria 1, an efficacy of 70% and 99% are correctly classified, with high probability (>95%), as being 'reduced' and 'normal', respectively,
whereas a drug efficacy of 95% is classified as suspected in ~40% of the cases, ~20% of the cases as 'reduced', and ~40% of the cases as 'normal'. Figure 3 illustrates the diagnostic performance of detecting reduced efficacy based on classification criteria 1, 2 and 3 for both 95% UI methodologies separately. Compared to method 1, the sensitivity of detecting reduced efficacy was comparable for method 2, and this was the case for the three classification criteria (criteria 1: method 1 = 90.0% vs. method 2 = 91.0%; criteria 2: method 1 = 80.3% vs. method 2 = 80.8%; criteria 3: method 1 = 77.1 vs.
method 2 = 78.0%). Differences in specificity, however, were more pronounced. When applying method 1 to calculate 95% UI, the specificity equaled 81.2% (criteria 1 and 3) and
54.2% (criteria 2), whereas this was 71.1% (criteria 1 and 3) and 44% (criteria 2) when applying method 2.
<Figure 3 near here> 3.3. The required sample size and the number of eggs to be counted under the microscope Based on the results described in sections 3.1. and 3.2. it was concluded that criteria 1 allowed for the most reliable detection of reduced efficacy (highest sensitivity and second highest specificity), and that neither of the UI methodologies was better than the other. Therefore, the required sample size and the number of eggs to be counted under the microscope were determined applying classification criteria 1 for the two 95% UI methodologies separately.
For the sensitivity, the logistic regression models predicted the observed data in ~93% of the cases (method 1 = 93.3%, method 2 = 93.6%), and for the specificity this was 81.3% and 76.6% for methods 1 and 2, respectively. Table 2 provides the required egg numbers required to correctly classify a TDE of 97%, 98% and 99% as 'normal' and a TDE of 87%, 88% and 89% as 'reduced' with a probability of at least 95% for a sample size of 5, 10, 15, 20 and 25 for the two different methodologies for calculating UIs. In most cases, the number of eggs to be counted under the microscope decreased when the sample size increased and increased when the TDE approached the threshold of 95%. The required egg counts for correctly classifying a truly reduced drug efficacy is generally higher than the number of eggs required for classifying a truly normal drug efficacy, but this difference in the required number of eggs to be counted also varies between the methods applied. For example, when applying method 1, the model predicts that counting ~200 eggs over 15 animals allows one to classify a truly normal drug efficacy of 98% in 95% of the cases as 'normal', where as this number of eggs only yields a correct classification of a truly reduced efficacy of 87%. When applying method 2, the model predicts ~200 eggs over 15 animals will also allow to classify a truly reduced efficacy of 87%, but may only allow to classify a truly normal drug efficacy of 99% in 95%
of the cases. For UI method I, the decrease in number of eggs to be counted with increasing sample size was small (TDE = 97%) to absent (TDE = 89%) when the TDE approached the threshold of 95%. Note that we have not reported the number of eggs that allow correctly classifying drugs with a truly underlying efficacy between 89% and 97%, and this is because these numbers are logistically not feasible to be obtained under field conditions (>750 eggs).
<Table 2 near here>
Discussion
Despite increasing criticism of the existing WAAVP recommended guidelines for FECRT published almost 25 years ago in 1992, and the recent progress made on how to best design, analyze and interpret a FECRT, there remains a lack of important evidence to support the revision of the current guidelines. In this study we aimed to address this lack of evidence, with the goal of providing insights complementary to the current knowledge, and to ultimately provide guidance that allows improving both the standardization and the performance of the FECRT with applicability across a variety of both host and parasite species. To this end, we consecutively compared different classification criteria and UI methodologies. Based on the results obtained, we determined the required samples size and number of eggs to be counted under the microscope that optimize the detection of reduced efficacy.
Our results show that a number of the parameters in the current FECRT guidelines (Coles et al., 1992) require modification. However, our analyses also indicate that the classification criteria provided in the current guidelines, based on the FECR and the LL of the 95% UI, is the best strategy for classifying drug efficacy. Compared to the other classification criteria for FECRT results, these criteria provided the highest sensitivity for detecting a truly reduced efficacy, while providing the second highest specificity. Overall, these criteria yielded the A C C E P T E D M A N U S C R I P T highest probability for correctly classifying drug efficacy of the four classification criteria tested. Admittedly, the thresholds put forward by Coles et al. (1992) of 95% for FECR and 90% for the LL of the UI are somewhat arbitrary. Once efficacy falls below 99%, both the actual reduction in efficacy and variability come into play. If the efficacy is lower than expected due to random variability, then a conclusion of reduced efficacy is reasonable. Thus, choice of the threshold is not merely a statistical issue, but also a biological one (Vidyashankar et al, 2012) . Consequently, any threshold chosen will be arbitrary by its very nature. Given the usual expected efficacies of commonly used anthelmintics of >99%, and the limitations of precision when performing a FECRT, the choice of 95% FECR and LL of UI of 90% remain sensible and useful thresholds. One could increase the thresholds and improve specificity, or decrease the thresholds and improve sensitivity, but the inherent tradeoff makes it impossible to maximize both simultaneously. All four of the classification criteria tested in our analyses used various permutations of the 95% and 90% levels for FECR and 95% UI, respectively. If different thresholds were used, the measured values for sensitivity and specificity of each classification criteria would change, but it is likely that the same conclusions would be reached. Thus, the results of our analyses suggest that revision of the current classification criteria is not justified.
Making recommendations on the UI methodology revealed to be less straightforward.
Compared to the methodology based on Levecke et al., 2015 , the methodology described by Lyndal-Murphy et al., 2014, resulted in a higher coverage of the TDE (lower LL), approaching the expected coverage 95%, but often failed to correctly classify a truly normal drug efficacy. Although this poor specificity of the methodology described by LyndalMurphy et al., 2014 could be resolved by either including more animals or counting more eggs under the microscope (Table 2) , it will come with additional costs. For example, processing and examining further samples with McMaster (analytic sensitivity of 50 EPG)
requires 5 -6 minutes/sample (Levecke et al., 2009; Barda et al., 2014; Van den Putte, 2016) , whereas this is 12 -13 min for Mini-FLOTAC (analytic sensitivity 5 -10 EPG; Barda et al., 2014; Van den Putte, 2016 ) and 28 -37 min for FLOTAC (analytic sensitivity of 1 -2 EPG; Speich et al., 2010) . In practice additional sampling requires that the original sample material is preserved while the first set of counts are completed and that a decision on the necessity to count more samples needs to be determined at the time. In addition, these UI methodologies do not allow the assessment of uncertainty when the FECR equals 100% and when pre-and post FECs are perfectly positively correlated. To illustrate these cases in more detail we have worked out a toy example in Supplementary Material 2. It is important to note that the data used in this example are not generated using the methodology described in 2.1. Data generation, neither do they represent real field data, rather they are both arbitrary and purposively generated to clearly illustrate the limitations of each UI methodology. For example, although it is likely to observe a FECR 100% when pre-FECs are low and when the analytic sensitivity of the FEC method is high (increases false negatives), an observed perfect correlation between observed pre-and post-FEC is virtually unlikely to occur. A variety of alternative Bayesian based methodologies have been described that allow to assess the uncertainty around the FECR estimates in these cases, and hence to draw conclusions on the efficacy of the drugs (Bayescount: Denwood et al., 2010; Geurden et al., 2015; Peña-Espinoza et al., 2016; Jeffrey's interval: Dobson et al., 2012 : eggCounts: Torgerson et al., 2014 .
However, these methodologies too have some important limitations, which impede recommending one methodology to estimate the uncertainty. Jeffrey's interval does not account for the variation and the correlation of counts at pre-and posttreatment, and as a consequence of this, it is not appropriate for a design based on pre-and post-FECs of the same animals. This is made more explicit in Supplementary Material 2, which shows that swapping post-FECs across individuals will not result in a change in the
95% UIs when Jeffrey's interval is applied. The implementation and the interpretation of both Bayescount (Denwood et al., 2010; Geurden et al., 2015; Peña-Espinoza et al., 2016) and eggCounts (Torgerson et al., 2014 ) still require a high-level knowledge on statistics, which poses an important obstacle for their usability. Efforts in developing web interfaces to make a bridge between this relatively complex framework and the end-users, who are less experienced in statistics, should be further encouraged (eggCounts:
http://www.math.uzh.ch/ag/?id=252). Moreover, important differences between both Bayesian methodologies have recently been observed, eggCounts generally reporting more narrow UIs compared to those of Bayescount (Peña-Espinoza et al., 2016) , and these discrepancies in width also became apparent in the toy example described in Supplementary Material 2. EggCounts did not result in wider UIs when post-FECs were swapped, suggesting that the UIs derived from this model may not completely reflect a true underlying variation in drug efficacy across animals in a paired test. Also note that earlier implementations of the eggCounts (before October 2016) did not provided wider UIs, even when it was assumed that the FECs were obtained through a randomized controlled study design using post-treatment counts of both treatment and control groups. The latest implementation has corrected this error (version 1.3; Wang et al. 2017) . It is out of the scope of the current study to explain these observed differences both between and within Bayescount and eggCounts in more technical detail, but it is important to underline the potential impact of these differences on drawing conclusions. This is in particular when inference is drawn based on UIs, including but not limited to classifying drug efficacy based on FECRT. For example, Kotze and colleagues (2014) applied eggCounts to verify whether inclusion or exclusion of low pretreatment FECs (<150 EPG) would affect the FECR results in 2 human clinical trials designed to assess the efficacy of albendazole against hookworm infections. In one of these human trials exclusion of the low pre-treatment FECs resulted in a significant higher FECR-result.
applied the methodology of Levecke et al., 2015) , and therefore the likelihood that UIs do not overlap increases. As a consequence of this, the probability of falsely rejecting the null hypothesis that there is no difference in FECR results may have increased. Other studies that applied the earlier versions of eggCounts, and hence results from unpaired designs in these studies may need to be interpreted with caution. These include Malrait et al. (2014) 100% is observed in a study, in order to estimate the reliability (UIs) of that result we would recommend to apply Bayescount (Denwood et al., 2010; Geurden et al., 2015; Peña-Espinoza et al., 2016 ), Jeffrey's interval or eggCounts (Torgerson et al., 2014: http://www.math.uzh.ch/ag/?id=252) despite the limitations of these methods in other contexts. Table 2 provides the required sample size and the total number of eggs to be counted under the microscope across a wide range of TDE values. These values should now allow researchers to design their FECRT according to a wide range of field conditions and without prior knowledge on the egg excretion in the animals, while ensuring a good diagnostic performance of detecting reduced efficacy. This analysis also confirms that (i) the diagnostic performance of the FECRT improved as a function of sample size and the number of eggs counted under the microscope in almost all cases, the latter being a function of the analytic sensitivity of the diagnostic technique, and the intensity and aggregation of egg excretion; (ii) that there will always be a grey zone in which it remains unreliable to draw conclusion on the efficacy of drugs based on FECRT ( Figure 3) ; and (iii) that it requires more animals and number of eggs to be counted to correctly classify a truly reduced drug efficacy than a truly normal drug efficacy (Table 2 ; Levecke et al., 2012) . For example, when 200 eggs are
counted across 15 animals a TDE down to 98% (3% point from the 95% threshold) can be correctly classified as normal with a probability of at least 95% (UI method 1), whereas this same design allows, with an equal level of confidence, classifying a drug efficacy only up to 87% (8% point difference from the 95% threshold). This different performance in classifying truly reduced and normal drug efficacy can be explained by the decrease in variance of FECR as a function of increasing drug efficacy (see formulae for calculating variance of FECR; Levecke et al., 2015) . As a consequence of this, one may not extrapolate the required sample size and number of eggs to be counted across thresholds, and this is made evident in Supplementary Table 1 . This table reports the required sample size and number of eggs counted to correctly classify truly reduced drug efficacy based on FECRT when a thresholds of 95% (LL of UI) and 99% (FECR) are used. Not surprisingly less animals and numbers of eggs need to be counted to correctly classify a truly reduced efficacy using these thresholds, in casu counting 150 eggs across 5 animals allows correctly classifying TDEs up to 93% (6% point difference to 99%) as reduced in 95% of the cases. Also note the difference in required number of eggs to be counted between UI methods. The methodology described by Levecke et al., 2015 requires less eggs to be counted when sample size is small compared to the methodology described by Lyndal-Murphy et al., 2014, but requires more eggs when sample size increases. Moreover, for the UI method described by Levecke et al. (2015) the number of eggs to be counted increased with the sample size, but only when the TDE equaled 94%. The latter observation is the result of the three-way interaction in the model (TDE x sample size x total number of eggs counted), as omission of this interaction resulted in a decrease in the total number of eggs to be counted as a function of sample size across all scenarios of TDE.
Because the fully parameterized model resulted in a significant better goodness-of-fit, we decided not to omit the interaction from the model.
This study has some important limitations that need to be acknowledged. First, the conclusions drawn are applying prediction models on data generated through simulation.
Although the assumptions made for data generation in this simulation have been previously applied in other simulation studies (Torgerson et al., 2005; Dobson et al., 2009; LyndalMurphy et al. 2014) and have been proven to be valid in some animal and parasite species (Morgan et al., 2005; Torgerson et al., 2012) , they may not fully explain the variation observed in real data (e.g., day-to-day variation in egg excretion; variation in egg counts of the same sample across laboratory technicians), and hence the required sample size and number of eggs counted under the microscope might be biased. Moreover, predictions were based on models that, not surprisingly, fail to correctly predict all the data, and hence this too may have an impact on the required sample size and the total number of eggs counted.
Second, we did not consider any continuing larval development, though the impact of this In conclusion, optimal interpretation of FECRT data requires the ability to distinguish genuine reductions in efficacy from changes in efficacy due to sampling variability. In order to address this issue in a meaningful way, it is necessary to use data simulation and statistical
analyses to determine the optimal parameters for performing the FECRT and for analyzing the resulting data. This study has used such an approach in an attempt to provide insights complementary to the current knowledge on how to optimally design, analyze and interpret FECRTs, and to ultimately provide guidance that allows improving both the standardization and the performance of the FECRT across a variety of both animal and parasite species. Our results confirm that the current criteria to classify drug efficacy are the most appropriate, but highlights that the UI methodologies vary considerable in coverage and ability to detect a truly reduced drug efficacy, and that a combination of UI methodologies is recommended to assess the uncertainty across all possible FECRT scenarios. Finally, based on model estimates researchers can now determine the required number of eggs to be counted for each sample size allowing one to optimize the probability of correctly classifying a theoretical TDE while minimizing both financial and technical resources. Criteria 1 classifies a drug efficacy as 'reduced' when FECR <95% and lower limit (LL) of the 95% uncertainty interval (95%UI) <90%, as 'suspected' when either FECR <95% or LL <90%, and as 'normal' when FECR ≥95% and LL ≥90%. The criteria 2 classifies a drug efficacy as 'reduced' when the UL of the 95%UI is <95%, as 'suspected' when FECR <95%, but 95% is included in the UI or when FECR ≥95%, but when the LL <95%, and as 'normal' when the LL ≥95%. Criteria 3 classifies drugs as 'normal' when FECR ≥95%, UL UI ≥95%
and lower UI ≥90%, as 'reduced' when FECR <95%, UL UI <95% and lower UI <90%, and as 'suspected' in all other cases. Criteria 4 classifies drug efficacy solely based on the observed FECR result, drug efficacy being 'reduced' when the FECR <90%, 'suspected' when FECR ≥90% but <95%, and 'normal' FECR ≥95.
A C C E P T E D M
A N U S C R I P T Table 2 . The required sample size and total number of eggs to be counted under the microscope to correctly classify a truly reduced (true drug efficacy <95%) and normal drug efficacy (true drug efficacy ≥95%) with a probability of at least 95% for two different methodologies of calculating 95% uncertainty intervals (UIs; method 1; method 2). 
Sample size True drug efficacy (%)
